On November 3, CANSINOBIO fell 5.06% in Regular Trading, trading at HK$24.4, with turnover of HK$35.6517 million.

The latest company-specific update was a change in continuous supervision sponsor representatives, with CITIC Securities appointing Wang Tianqi to replace Xu Fenglin alongside Jiao Yanyan. The change was procedural and did not alter the company’s ongoing supervision arrangements.

Recent results provide more direct operating context: for the first three quarters, revenue rose 27.40% to RMB882 million and attributable net profit increased 12.82% to RMB16.29 million, but third-quarter net profit was RMB17.01 million, down 39.08% year over year. The company also disclosed impairment charges and deferred tax asset write-downs that together affected net profit by about RMB33.03 million. In the Biotechnology sector, several peers were also weaker, including AKESO falling 2.73%, BEONE MEDICINES falling 4.35%, INNOVENT BIO falling 1.98%, and SKB BIO falling 7.62%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)